Eflornithine 8.5% (Hirsutism)

Route: Topical cream, applied to affected facial areas.

• Apply a thin layer to affected facial areas (e.g., upper lip, chin) twice daily, at least 8 hours apart.
• Rub in thoroughly until fully absorbed; do not wash the treated area for at least 4 hours after application.
• May apply cosmetics or sunscreen over the cream after it has dried.
• Eflornithine does not remove hair — patients should continue their regular hair removal routine, applying the cream 5 minutes after hair removal.
• Avoid contact with eyes and mucous membranes.

Dosing is prescriber-directed. Standard reference dosing for eflornithine topical cream:

• Apply a thin layer to affected facial areas twice daily (approximately every 12 hours).
• Rub in completely. Treatment must be continuous to maintain effect; hair regrowth returns to pre-treatment levels within 8 weeks of discontinuation.
• Initial clinical improvement in hair growth rate is typically observed within 4–8 weeks of consistent twice-daily application.

• Eflornithine HCl: A "suicide inhibitor" that irreversibly binds and inactivates ornithine decarboxylase (ODC) at its active site via covalent interaction with Cys-360, catalyzed by cofactor pyridoxal 5'-phosphate (PLP). ODC is the first and rate-limiting enzyme in the polyamine biosynthesis pathway, catalyzing the decarboxylation of ornithine to putrescine, the precursor to spermidine and spermine. Polyamines are essential for cell proliferation, DNA stabilization, and keratin synthesis in hair matrix cells. By inhibiting ODC, eflornithine reduces the rate of hair follicle cell proliferation and shortens the anagen (growth) phase, resulting in slower hair regrowth without removing existing hair.

Clinical Context: Eflornithine topical cream is indicated for the reduction of unwanted facial hair growth (hirsutism) in women, regardless of the underlying cause of excess hair growth (PCOS, idiopathic, medication-induced, or congenital adrenal hyperplasia-related). It is typically used as an adjunct to hair removal methods (shaving, waxing, laser, electrolysis) to reduce the frequency of removal and improve cosmetic outcomes. The commercially available product (Vaniqa® 13.9%) is FDA-approved; this 8.5% compounded concentration is prescribed at the clinician's direction for individualized patient care.

Monitoring:

• Clinical assessment of hair growth rate reduction at 8–12 weeks (photographs or patient self-report).
• Skin tolerance monitoring: assess for acne, folliculitis, stinging, and contact dermatitis at application sites.
• If no clinical improvement is observed after 4–6 months of consistent use, reassess the diagnosis and treatment plan.
• For underlying endocrine causes of hirsutism (PCOS, elevated androgens), concurrent treatment of the etiology is appropriate.

Contraindications:

• Hypersensitivity to eflornithine or any cream excipient.
• Application to skin with open wounds, cuts, or abrasions — may increase systemic absorption.

Warnings & Precautions:

• For external use only; avoid eye and mucous membrane contact.
• Stinging and burning may occur if applied to irritated, broken, or recently shaved skin.
• Transient acne, folliculitis, or pseudofolliculitis may develop at application sites — typically mild.
• If skin rash, severe irritation, or signs of allergic contact dermatitis occur, discontinue use.
• Renal impairment: systemic absorption from topical use is minimal; however, patients with severely reduced renal function may accumulate eflornithine — though doses from topical use are far lower than systemic dosing, caution is warranted.
• Pregnancy and lactation: systemic absorption is low with topical use; risk-benefit should be discussed with the prescriber.

Drug Interactions:

• Eflornithine does not significantly inhibit CYP450 enzymes and has a low systemic absorption profile from topical use; clinically significant drug interactions are not expected.

Common Side Effects: Stinging, burning, skin tingling or numbness at application site, acne, folliculitis, pseudo-folliculitis barbae, erythema, and skin rash. Most side effects are mild and localized to the treatment area.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from light. Keep container tightly closed. Keep out of reach of children. Use before the beyond-use date assigned by Genesis Compounding. Do not use if cream appears discolored or has an unusual odor.

Will eflornithine remove my facial hair?

No. Eflornithine slows the rate of hair regrowth by inhibiting an enzyme in hair follicle cells; it does not remove existing hair. Patients should continue their chosen hair removal method and apply the cream after removal, continuing twice-daily applications to maintain the growth-slowing effect.

How long before I see results?

Clinical improvement in hair growth rate is typically observed after 4–8 weeks of consistent twice-daily use. Some patients may require up to 6 months. If no benefit is apparent after 4 months, the prescriber should be consulted to reassess the treatment plan.

What happens if I stop using this cream?

Hair regrowth returns to pre-treatment rates within approximately 8 weeks of discontinuing eflornithine. The drug does not permanently alter hair follicles; treatment must be continued to sustain effects.

Why is this 8.5% and not the 13.9% Vaniqa® formulation?

The FDA-approved Vaniqa® cream contains 13.9% eflornithine (as monohydrate hydrochloride). This compounded 8.5% preparation is prescribed at the clinician's direction for a patient-specific indication or preference. The prescriber has determined this strength to be appropriate for the individual patient's needs.

Is this safe to use long-term?

Topical eflornithine has a favorable safety profile with low systemic absorption. Long-term use data from clinical studies support sustained twice-daily use for control of facial hirsutism. The most common issues are localized skin reactions, which are typically mild and transient.